Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

  • 1Email author,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1
BMC Psychiatry20055:44

https://doi.org/10.1186/1471-244X-5-44

  • Received: 25 November 2005
  • Accepted: 30 November 2005
  • Published:

The original article was published in BMC Psychiatry 2005 5:5

The comment in the introduction of our article [1] suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics [2].

Notes

Authors’ Affiliations

(1)
MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa
(2)
Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada

References

  1. Carey PD, Vythilingum B, Seedat S, Muller JE, van AM, Stein DJ: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005, 5: 5-10.1186/1471-244X-5-5.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000, 68: 29-39. 10.1016/S0024-3205(00)00911-5.View ArticlePubMedGoogle Scholar
  3. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/5/44/prepub

Copyright

Advertisement